■胱抑素SA(CST2)在不同类型的恶性肿瘤中起着多种作用;然而,其在浆液性卵巢癌(SOC)中的作用尚不清楚.因此,我们的目的是调查表达水平,生存结果,免疫细胞浸润,扩散,细胞周期,以及与SOC中CST2信号相关的潜在分子机制。
癌症基因组图谱数据库用于从SOC患者获得临床信息和CST2表达谱。使用Wilcoxon秩和检验比较SOC和正常卵巢组织之间的CST2表达水平。使用Cox回归分析和Kaplan-Meier方法对CST2进行预后评估。使用功能富集分析鉴定差异表达的基因。使用单样品基因集富集分析检查免疫细胞浸润。使用集落形成试验评估细胞周期特征和增殖,流式细胞术,和细胞计数试剂盒-8测定。采用Western印迹和定量逆转录PCR分析来检查CST2表达和涉及细胞周期和Wnt-β-catenin信号传导途径的相关基因。
■我们的发现揭示了CST2在SOC中的显著上调,CST2表达升高与晚期临床病理特征和不良预后相关。通路富集分析强调了细胞周期和Wnt信号通路之间的关联。此外,CST2水平升高与免疫细胞浸润呈正相关。功能上,CST2在促进细胞增殖中起重要作用,协调G1到S的相变,并通过激活Wnt-β-catenin信号通路驱动恶性SOC进展。
■CST2的表达升高可能通过激活Wnt-β-catenin通路与SOC的发生和进展有关。此外,我们的研究结果表明,CST2是一种有前途的新型生物标志物,具有潜在的治疗应用,预后,和SOC的诊断策略。
浆液性卵巢癌是一种死亡率高的妇科恶性肿瘤。了解这种疾病对于改善治疗和提高患者生存率至关重要。在我们的研究中,我们研究了一种名为CST2的蛋白质及其在浆液性卵巢癌中的作用.我们发现CST2水平因患者而异,并且与癌症的进展和患者的预后有关。这对未来的诊断和治疗策略可能是有价值的。然而,需要进一步的研究来验证这些发现.尽管有其局限性,我们的研究结果表明,CST2有望成为检测浆液性卵巢癌的潜在生物标志物,并成为此类癌症患者治疗的治疗靶点.
UNASSIGNED: Cystatin SA (
CST2) plays multiple roles in different types of malignant tumours; however, its role in serous ovarian cancer (SOC) remains unclear. Therefore, we aimed to investigate the expression levels, survival outcomes, immune cell infiltration, proliferation, cell cycle, and underlying molecular mechanisms associated with the CST2 signature in SOC.
UNASSIGNED: The Cancer Genome Atlas database was used to acquire clinical information and
CST2 expression profiles from patients with SOC. Wilcoxon rank-sum tests were used to compare CST2 expression levels between SOC and normal ovarian tissues. A prognostic assessment of CST2 was conducted using Cox regression analysis and the Kaplan-Meier method. Differentially expressed genes were identified using functional enrichment analysis. Immune cell infiltration was examined using a single-sample gene set enrichment analysis. Cell cycle characteristics and proliferation were assessed using a colony formation assay, flow cytometry, and a cell counting kit-8 assay. Western blots and quantitative reverse transcription PCR analyses were employed to examine CST2 expressions and related genes involved in the cell cycle and the Wnt-β-catenin signalling pathway.
UNASSIGNED: Our findings revealed significant upregulation of
CST2 in SOC, and elevated
CST2 expression was correlated with advanced clinicopathological characteristics and unfavourable prognoses. Pathway enrichment analysis highlighted the association between the cell cycle and the Wnt signalling pathway. Moreover, increased
CST2 levels were positively correlated with immune cell infiltration. Functionally, CST2 played vital roles in promoting cell proliferation, orchestrating the G1-to-S phase transition, and driving malignant SOC progression through activating the Wnt-β-catenin signalling pathway.
UNASSIGNED: The elevated expression of CST2 may be related to the occurrence and progression of SOC by activating the Wnt-β-catenin pathway. Additionally, our findings suggest that CST2 is a promising novel biomarker with potential applications in therapeutic, prognostic, and diagnostic strategies for SOC.
Serous ovarian cancer is a type of gynecological malignant tumour with high mortality rates. Understanding this disease is crucial for improving treatments and enhancing patient survival. In our study, we investigated a protein called
CST2 and its role in serous ovarian cancer. We found that CST2 levels vary among patients and are associated with the progression of cancer and the prognosis of the patient, which could be valuable for future diagnosis and treatment strategies. However, further research is needed to validate these findings. Despite its limitations, our findings suggest that CST2 holds promise as a potential biomarker for detecting serous ovarian cancer and as a therapeutic target in the management of patients with this type of cancer.